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Abstract. People with cystic fibrosis (CF) must endure up to four hours treatment per day
to maintain health and are vulnerable to complications. The Cystic Fibrosis Quality of Life
Questionnaire was developed to measure health related quality of life (HRQoL) in the UK.
Most studies on HRQoL are cross-sectional in design with HRQoL measured once per
patient. However, the Cystic Fibrosis Quality of Life Questionnaire has been used to
monitor HRQoL longitudinally with measures taken over a 12 year period at one clinic in
the UK. These data were modelled with a binomial distribution for a domain score and with
fixed and random coefficients for the patient-level clinical and demographic variables.  The
longitudinal study included 182 patients whose HRQoL was first measured within a single
calendar year and were then followed-up. These data provided an opportunity to compare,
directly and by simulation, the modelling of a cross-sectional with a longitudinal study and
so provided insights into the statistical merits of longitudinal studies compared to cross-
sectional studies in HRQoL.
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1. INTRODUCTION
In the white population, cystic fibrosis (CF) is the most common autosomal
recessive condition (Rosenstein, 1998). For people with this condition, the lungs,
digestive system and other organs become affected by thick and sticky mucus
because their cells are unable to regulate the production of sodium and chloride. In
2013 in the UK alone, 10,000 children and adults were receiving care in CF clinics
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and were registered with the UK CF Registry (UK Cystic Fibrosis Registry, 2014).
People with CF require a treatment regimen of up to four hours per day to maintain
optimal health and are vulnerable to many complications such as CF related
diabetes, pneumothorax, osteoporosis and lung infections such as with B. cepacia
complex. They also find it a significant challenge to obtain sufficient nutrition from
their dietary intake. Despite this, in recent years in the UK at least, CF has ceased
to be a disease only of childhood since now, with good medical care and rigorous
daily treatment, many people with CF reach adulthood and move on into adult life,
enter training or attend university, obtain employment and participate in adult social
and family life (Laborde-Castérot  et al., 2012). Even so, median age at death was
29 years for deaths occurring in 2013, though some individuals had survived into
their late fifties and beyond (UK Cystic Fibrosis Registry, 2014). Clearly health
related quality of life (HRQoL) is an important issue for people with CF and good
psychological and mental well-being is essential, also, to allow people to comply
with their treatment and maximise their longevity and their life chances (Abbot,
2009; Abbott et al., 2011).
Many cross-sectional studies have investigated the effects of clinical and
demographic variables on HRQoL in CF (Gee  et al., 2003, Gee  et al., 2005, Wahl
et al., 2005). In contrast there are few studies which have looked at HRQoL
prospectively in a truly longitudinal manner (Abbott et al., 2013; Abbott et al.,
2015).  Such long-term studies may take a decade or more to complete (Abbott  et
al., 2013; Abbott  et al., 2015) and research funding streams are rarely able to
provide the necessary long-term support. Some studies which are described as
longitudinal can be better understood as cross-sectional studies with either a single
follow-up time for each patient (Sawicki  et al., 2011) or have many assessments on
the same patient but over a short time scale (Goldbeck et al., 2007) and it is
questionable whether these are bona-fide longitudinal studies. So, in point of fact,
real longitudinal studies in HRQoL are very rare whereas cross-sectional studies
are not. From the point of view of epidemiology, longitudinal studies may be
preferable to cross-sectional studies because they allow the assessment of cause and
effect and longitudinal studies can show temporality which cross-sectional studies
cannot always demonstrate. In the study of marketplace behaviours, the relative
validity of longitudinal and cross-sectional surveys has been discussed in the
context of common methods variance and valid causal inference (Rindfleisch et al.,
2008). However, from the point of view of statistics, it is not clear what are the
advantages of longitudinal over cross-sectional studies in terms of HRQoL model
estimation and the assessment of the contribution of demographic and clinical
changes to changes in HRQoL. This was due mostly to a lack of available genuine
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longitudinal data in the past to inform a statistical comparison. Now, however,
suitable longitudinal study data have become available (Abbott et al., 2013, 2015)
and some comparisons have become feasible. This study provides a comparison
based on direct modelling of the empirical data followed by a computer simulation.
2. THE LONGITUDINAL AND CROSS-SECTIONAL DATA
A longitudinal study engaged patients attending a single CF clinic in the north-east of
England in 1998 and followed-up patients every two years until 2010. Thus patients had
a maximum of 7 assessments in total.  Patients sometimes failed to attend clinic and
sometimes moved to a different clinic (for example when away at university) and sadly
some patients died. Hence between 1 and 7 assessments were made for the patients and
the first assessments were made during the calendar year 1998.  At assessment, the
demographic variables of gender and age and a range of clinical variables were
recorded; weight, height, body mass index (BMI), lung function measured by forced
expiratory volume in one second adjusted for age, gender and height (FEV1% predicted),
whether the patient was on oral nutritional supplements or was taking enteral tube feeds,
whether the patient was diagnosed with CF-related diabetes, infected in the lung with
B. cepacia complex, had a totally implantable vascular access device (TIVAD) fitted for
antibiotic treatment, and whether they were on a waiting list for organ transplantation
or had already received a transplantation.
HRQoL was measured using the CFQoL tool (Gee et al., 2000) which was
developed and validated for the UK CF population and comprised nine domains of
HRQoL; Physical functioning, Social functioning, Emotional responses, Treatment
issues, Chest symptoms, Body image, Interpersonal relationships, Career concerns
and Concerns for the future. The data for the demographic, clinical and HRQoL
variables were complete for all patients when they attended clinic for assessment
and no variable values were missing in the longitudinal data.
Table 1: Numbers of observations in the cross-sectional and the longitudinal data.
Cross-sectional data Longitudinal data
Number of Patients Patient- Patients Patient-
bi-annual times points assessments assessments
1 182 182 40 40
2 37 74
3 17 51
4 26 104
5 21 105
6 19 114
7 22 154
Total 182 182 182 642
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The cross-sectional data were obtained by selecting the first assessment, taken
during 1998, for each patient. If a longitudinal study had not gone ahead then the
1998 data would have comprised a cross-sectional study. Effectively the cross-
sectional data was a subset of the longitudinal data collected over a single calendar
year. Table 1 shows the number of patients (n=182) in the cross-sectional and
longitudinal data and the numbers of patient-assessments in the longitudinal data
(n=642 patient-assessments) together with the numbers of times the patients were
assessed. Table 2 shows the summary statistics for the cross-sectional and the
longitudinal data. Fortuitously, the cross-sectional and the longitudinal data have
the same range for BMI, FEV1% predicted and all HRQoL domains have a similar
age range and the clinical variables are not very different between the two data sets.
Had this not been the case, a comparison between cross-sectional and longitudinal
models may not have been valid.
Table 2: Summary statistics of the demographic, clinical and health related quality of life
measures in the cross-sectional and longitudinal data.
Cross-sectional data Longitudinal data
182 patients 182 patients
182 patient-assessments 642 patient-assessments
N (%) N (%)
Female gender 105 (57.7%) 379 (59.0%)
CF related diabetes 56 (30.8%) 256 (39.9%)
Oral supplements 60 (33.0%) 213 (33.2%)
Enteral tube feeds 35 (19.2%) 104 (16.2%)
TIVAD 86 (47.3%) 340 (53.0%)
B. cepacia complex 14   (7.7%) 52   (8.1%)
Listed for transplant 8   (4.4%) 26   (4.0%)
Received transplant 17   (9.3%) 93 (14.5%)
Mean (SD) Range Mean (SD) Range
Age (years) 24.4   (6.9) 14-51 28.7   (8.1) 14-57
BMI 21.4   (2.9) 15.7-30.2 21.7   (2.8) 15.7-30.6
FEV1% predicted 59.2 (24.2) 12-133 57.8 (23.2) 12-133
Physical functioning % 83.2 (21.4) 2-100 83.2 (20.2) 2-100
Social functioning % 83.4 (22.2) 0-100 84.4 (21.7) 0-100
Emotional responses % 79.1 (20.9) 8-100 79.3 (19.8) 8-100
Treatment issues % 78.0 (21.7) 0-100 75.4 (22.2) 0-100
Chest  symptoms % 75.5 (24.1) 0-100 76.4 (22.8) 0-100
Body image % 68.8 (25.3) 0-100 69.9 (24.9) 0-100
Interpersonal relationships % 63.9 (22.1) 2-100 63.7 (22.4) 2-100
Career concerns % 63.5 (28.9) 0-100 61.5 (29.5) 0-100
Concerns for the future % 46.6 (24.6) 0-100 45.3 (24.7) 0-100
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3. MODELS FOR THE CROSS-SECTIONAL AND LONGITUDINAL DATA
Using the CFQoL (Gee et al., 2000), the quality of life of a patient on a domain was
measured as a percentage between 0% and 100% where the percentage was
obtained as 100S/N where S was the patient’s integer score for the domain and N was
the maximum domain score achievable. The maximum varied between the nine
domains; Physical functioning (50), Social functioning (20), Emotional responses
(40), Treatment issues (15), Chest symptoms (20), Body image (15), Interpersonal
relationships (50), Career concerns (20) and Concerns for the future (30). Modelling
HRQoL presented challenges because of the well-understood ‘ceiling’ effect in that
HRQoL is bounded above by 100% (Walters, 2009). For this reason a binomial
regression model was selected with a logistic link function between the binomial
probability and the linear predictor incorporating the demographic and clinical
variables. The binomial probability (expressed as a percentage) was assumed to
represent the patient’s true HRQoL on the domain. The linear predictor regression
model in turn was assumed to contain both fixed and random patient-specific
regression coefficients in order to model the correlation between HRQoL measures
on the same patient at the different times in the longitudinal data. The random
regression coefficients were assumed to be normally distributed over the population
of patients.  The models were fitted using the software MLwiN v2.1 (Rasbash et al.,
2009) and detailed descriptions of the algorithms used by MLwiN may be found in
Goldstein (2011).
For the longitudinal data, exploratory analyses resulted in a final selected
regression model in which the covariates FEV1% predicted, BMI and the model
intercept were included with random coefficients across patients, age was included
with a fixed coefficient and all categorical variables had fixed coefficients of
necessity. The choice between random or fixed coefficients for quantitative variable
was based on an assessment of whether the variance of a candidate random term was
negligible and also whether it had negligible covariance with other random
coefficients. The cross-sectional data, with one assessment per patient, could not
support the estimation of random coefficients for FEV1% predicted or for BMI but
could support the estimation of a random intercept. This was because the random
coefficients for FEV1% predicted and BMI were patient specific and one observation
per patient in the cross-sectional data would prevent the estimation of the variance
of the random coefficients. The random intercept however varied between patients
and so the intercept variance was estimable from the cross-sectional data.
The binomial denominators for the nine HRQoL domains ranged from 15 to
50 and the comparison between using the cross-sectional data and using longitudinal
data might depend on the size of the denominator; the smaller denominator possibly
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producing less sensitive data resulting in less precise estimates than with a larger
denominator. For this reason the comparison models were fitted to the CFQoL
domain of Physical functioning with a denominator of 50 and the domain of
Treatment issues with a denominator of 15. Tables 3 and 4 show the models fitted
to the cross-sectional and longitudinal data for the domains of Physical functioning
and Treatment issues respectively. Figure 1 and Figure 2 show the comparison bar
charts of the model coefficients together with plus and minus one standard error.
Table 3: Comparison of the estimated model coefficients between the cross-sectional and the
longitudinal data for the domain of Physical functioning.
Cross-sectional data Longitudinal data
Coefficient SE Coefficient SE
Categorical Fixed Categorical Fixed
Female gender 0.05 0.26 Female gender -0.12 0.21
CF related diabetes 0.25 0.27 CF related diabetes 0.03 0.09
Oral supplements -0.04 0.29 Oral supplements -0.05 0.09
Enteral tube feeds -0.30 0.40 Enteral tube feeds 0.27 0.13
TIVAD -0.65 0.27 TIVAD -0.38 0.09
B. cepacia complex -0.54 0.43 B. cepacia complex -0.36 0.19
Listed for transplant -0.93 0.62 Listed for transplant -0.24 0.14
Received transplant 0.39 0.44 Received transplant -0.36 0.22
Quantitative Fixed Quantitative Fixed
Age1 0.00 0.10 Age1 -0.11 0.03
Quantitative Random
BMI2 0.01 0.05 BMI2 Mean 0.10 0.04
BMI Variance 0.17 0.03
FEV1% predicted3 -0.15 0.07 FEV1% predicted3 Mean -0.20 0.05
Quantitative Random FEV1% predicted Variance 0.16 0.03
Intercept Mean 1.65 0.41 Intercept Mean 1.31 0.20
Intercept Variance 2.14 0.24 Intercept Variance 1.08 0.19
1 5-year increase, age centred on 30 years,  2 One unit decline, BMI centred on 20,  3 10% decline,
FEV1% predicted centred on 30%.
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Table 4: Comparison of model coefficients between the cross-sectional and the longitudinal
data for the domain of Treatment issues.
Cross-sectional data Longitudinal data
Coefficient SE Coefficient SE
Categorical Fixed Categorical Fixed
Female gender -0.14 0.20 Female gender 0.02 0.16
CF related diabetes 0.12 0.22 CF related diabetes -0.03 0.11
Oral supplements -0.40 0.23 Oral supplements -0.20 0.11
Enteral tube feeds -0.05 0.31 Enteral tube feeds 0.06 0.17
TIVAD -0.30 0.21 TIVAD -0.40 0.10
B. cepacia complex -0.35 0.33 B. cepacia complex -0.43 0.20
Listed for transplant -0.43 0.48 Listed for transplant -0.45 0.17
Received transplant 0.18 0.35 Received transplant 0.63 0.22
Quantitative Fixed Quantitative Fixed
Age1 0.02 0.02 Age1 -0.20 0.04
Quantitative Random
BMI2 0.08 0.04 BMI2 Mean 0.08 0.03
BMI Variance 0.02 0.01
FEV1% predicted3 -0.05 0.05 FEV1% predicted3 Mean -0.05 0.05
Quantitative Random FEV1% predicted Variance 0.07 0.02
Intercept Mean 1.52 0.33 Intercept Mean 1.13 0.20
Intercept Variance 1.03 0.15 Intercept Variance 0.85 0.17
1 5-year increase, age centred on 30 years, 2One unit decline, BMI centred on 20, 310% decline,
FEV1% predicted centred on 30%.
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Figure 2. Model coefficients for the cross-sectional data (light grey) and the longitudinal
data (dark grey) for the domain Treatment issues. Bars show plus and minus one
standard error.
Figure 1. Model coefficients for the cross-sectional data (light grey) and the longitudinal
data (dark grey) for the domain Physical functioning. Bars show plus and minus one
standard error.
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Not surprisingly, for both Physical functioning and Treatment issues, the
standard errors were larger for the cross-sectional data than for the longitudinal data
since the former were based on 182 assessments whereas the later were based on
642 assessments, albeit that the 642 assessments were not independent.  For
Physical functioning, the coefficients for ‘received transplant’ and for ‘enteral tube
feeds’ changed sign and for Treatment issues, the coefficient for ‘oral supplements’
also changed sign. The effect of age was negligible for both Physical functioning
and Treatment issues for the cross-sectional data but an age effect was clearly
evident for both in the longitudinal data.  The other coefficients were reasonably
consistent between the two data sets within the bounds of uncertainty as expressed
by the standard errors but the failure to detect and so adjust for the effect of
increasing age was a most concerning failure of the cross-sectional data.
4.  SIMULATION STUDY
When comparing the coefficients between the fitted models for the cross-
sectional and the longitudinal data, the true coefficients were unknown quantities
and hence a simulation study using known parameter values was performed to
provide additional insight into the comparison. Firstly, M patients were simulated
by selecting a bootstrap sample with replacement from the 182 patients. M took the
values 200, 650, 1300, 2600, 5200, 10400 in turn. Secondly, all of the demographic
and clinical variables at each assessment in sequence for a selected patient were
entered into the simulated longitudinal data and flagged as belonging to the ith
patient in the bootstrap sample. Thirdly, a HRQoL score, Qij, was calculated for the
simulated patient i at time j. Qij was obtained by calculating pij using the linear
equation:
logit(pij) = β0i – β1 Gi – (β2 /5)(ageij-30) – β3 Cij – (β4i /10)(FEV1%predictedij –30)
where β0i~ N(1.31,(0.2x1.31)2), β4i~ N(0.2,(0.2x0.2)2) and Covariance(β0i, β4i) =
0, β1 = 0.12, Gi = 0 when patient i was male and Gi =1 when patient i was female,
β2 = 0.11 and age was measured in years, centred on 30 years and β3 = 0.36, and Cij
= 0 when patient i did not have B. cepacia complex infection at time j and Cij = 1
when patient i had B. cepacia complex infection at time j.
Explaining this procedure in more detail, a bootstrap sample of size 182
patients was selected randomly with replacement from the 182 actual patients. Let
us say that person A was in this bootstrap sample and that person A had measure-
ments at four times, these times denoted by T1, T2, T3 and T4. For T1 person A’s
age, gender, FEV1% predicted and B. cepacia infection (present or absent) at time
T1 were used to generate by simulation person A’s QoL at time T1. Then the same
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procedure was used for times T2, T3 and T4. If another person, person B was also
in the bootstrap sample and person B had been measured at only two times, S1 and
S2 then their recorded values of age, gender, FEV1% predicted and B. cepacia
infection at times S1 and S2 were used to simulate their QoL at times S1 and S2
respectively. Once this procedure was carried out for all 182 in the bootstrap sample
a simulated data set was complete.
The standard deviations of the two normal distributions were chosen to
provide a 20% coefficient of variation for the patient-specific random coefficients
and the parameter scaling (5 years for age and 10 years for FEV1% predicted) was
chosen so that coefficients could be expressed to two decimal places in tables and
figures. Age was centred on 30 years and FEV1% predicted was centred on 30%
because these values limited the correlation between the parameter estimates for the
random coefficients in the models for the empirical data. Finally, once pij had been
calculated, score Qij was obtained by generating a random value from a binomial
distribution with probability pij and binomial denominator of either 50 or 15. The
computation of Qij for each denominator used the same bootstrap samples of
patients, but used independently generated values of the random coefficients β0i andβ4i and independently generated values from the binomial distributions. Upon
completion of a simulated longitudinal data set, a cross-sectional data set was
extracted by using the first time point for each simulated patient. This method
should generate a similar degree of correlation between estimated coefficients from
the simulated cross-sectional and longitudinal data as was observed in the empirical
data. The simulation was carried out in the R programming language (R Development
Core Team, 2010).
A simplified HRQoL model was chosen for the simulation study to make
results easier to interpret, but one of each type of variable was included. The
constant term was a necessity and could not be excluded. FEV1% predicted was
known to be related to eight out of the nine domains (Abbott et al., 2013) and was
a random patient-specific coefficient. Gender was a classifying factor which did not
change for patients over time and the cross-sectional data might be expected to
estimate a gender difference reasonably well. On the other hand, B. cepacia
complex infection was present for some patients at the first point but other patients
developed the infection at a later time point. If treated early and aggressively B.
cepacia complex infection can be eradicated and so, if a patient has the infection
at time j then they do not necessarily have the infection at subsequent times. The
effect of B. cepacia complex infection on HRQoL in the longitudinal data would
be established partly from the cross-sectional data subset and partly from the
subsequent longitudinal data. Age was a variable which the empirical data suggested
might be poorly estimated by cross-sectional data but which, a priori, was highly
likely to be an important predictor of HRQoL and hence age was included in the
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simulated models.
Table 5: Summary table for the simulation study showing (i) the longitudinal and cross-
sectional numbers of patients needed to achieve a target standard error of 30% of
the true coefficient value and (ii) the ratio of the numbers of patients required for a
cross-sectional study compared to a longitudinal study to achieve the same
coefficient standard errors.
Coefficient True Target Longitudinal Cross-sectional Ratio 95% CI
value SE sample size sample size
Maximum=50
Intercept 1.31 0.393 3 8 2.61 2.32 2.92
Gender 0.12 0.036 448 882 1.97 1.82 2.13
Age 0.11 0.033 35 129 3.63 3.30 4.02
B. cepacia comp. 0.36 0.108 114 260 2.28 1.93 2.68
FEV1% predicted 0.20 0.060 6 16 2.70 2.31 3.16
Maximum=15
Intercept 1.31 0.393 6 21 3.56 3.22 3.93
Gender 0.12 0.036 804 2363 2.94 2.73 3.15
Age 0.11 0.033 76 335 4.39 4.02 4.79
B. cepacia comp. 0.36 0.108 227 675 2.98 2.62 3.39
FEV1% predicted 0.20 0.060 13 42 3.18 2.78 3.63
Ratio sample size
Maximum=15 to Maximum=50 1.8 to 2.2 2.6 to 2.7
Figure 3 shows the estimated coefficients from the simulated cross-sectional
and longitudinal data for the increasing number of patients from 200 to 10,400. Any
bias would seem to be equal in extent for the cross-sectional and longitudinal data.
Figure 4 shows the estimated standard errors of the coefficients. Ordinary linear
regression of the logarithm of the estimated standard errors on the logarithm of the
simulated number of patients for each of the five variables and for both cross-
sectional and longitudinal data strongly supported the hypothesis that the standard
error of a coefficient was proportional to the square root of the number of patients,
at least to a good approximation. Consequently, the standard errors for each
coefficient were modelled by a simple linear regression which regressed yk where
yk = log(SEk) + 0.5log(Nk) on the indicator variable Dk which took the value  0 if
the standard errors were from a longitudinal study and 1 otherwise.  This allowed
the estimation of the multiplying factors by which we would need to increase the
number of patients to obtain the same precision of estimation in a cross-sectional
study as had been obtained from a longitudinal study. This, of course, assumed that
HRQoL was a function of age, gender, B. cepacia complex infection and FEV1%
predicted only. The ratios are shown in Table 5.
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Figure 3. Estimated coefficients for the longitudinal simulated data (solid line with
markers), for the cross-sectional simulated data (broken line with markers) and the
true value (solid line without markers) against the simulated number of patients.
Left-hand column is for a binomial denominator of 50 and-right hand column is for 15.
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Figure 4. Coefficient standard errors for the longitudinal simulated data (solid line with
markers), the cross-sectional simulated data (broken line with markers) against the
simulated number of patients. Left-hand column is for a binomial denominator of 50
and right-hand column is for 15.
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For example, if a longitudinal study had 100 patients, a HRQoL domain which
was measured out of maximum score of 50 (and had other characteristics similar
to this study) then a cross-sectional study would need 228 patients (100 x 2.28) to
achieve the same precision in estimation of the effect of B. cepacia complex
infection. For the age coefficient, 363 patients would be required in a cross-
sectional study compared to 100 in a longitudinal study. If the HRQoL domain had
a maximum score of 15 then the patients required for the cross-sectional study
would be 298 and 439 respectively for every 100 patients in the longitudinal study.
Table 5 also shows the number of patients needed in a longitudinal and a cross-
sectional study to achieve a standard error of 30% of the true value. A standard error
of about 30% should be adequate to detect significance of a clinical or demographic
variable. Table 5 is therefore a summary of the information contained in Figures 3
and 4.
The results presented in Table 5 support the following general insights:
(i) A longitudinal study of a fixed number of patients will offer far less precision
of estimation and lower power to detect the effect of clinical and demographic
variables for a HRQoL domain with a small maximum (e.g.15) compared to
a domain with a large maximum (e.g. 50).  The same is true for a cross-sectional
study. However, to obtain the same precision for a domain maximum of 15 as
for a domain maximum of 50 the increase in numbers of patients needs to be
by a factor of 1.8 to 2.2 for a longitudinal study. For a cross-sectional study the
factor needs to be 2.6 to 2.7. So, it would seem likely that longitudinal studies
better serve HRQoL domains with small maxima than cross-sectional studies.
(ii) Even in a longitudinal study, a relatively large number of patients might be
required to obtain a precise estimate of the effect of a demographic variable
such as gender which does not change longitudinally.
(iii) A longitudinal study with modest numbers of patients can estimate, with good
precision, the effect of increasing age. To estimate age with the same precision
in a cross-sectional study the number of patients would need to be multiplied
by 3.63 for domain maximum of 50 and 4.39 for domain maximum of 15.
Therefore, a cross-sectional study requires relatively more assessments than a
longitudinal study to achieve the same precision for the effect of age.
(iv) The estimation of the effect of a variable such as B.cepacia complex infection
which does change with time would seem to be equally well estimated by a
cross-sectional survey as by a longitudinal survey with similar numbers of
assessments.
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5. DISCUSSION
The empirical demographic and clinical data used for the simulations had 642
patient-assessments for 182 patients providing an average of 3.5 assessments per
patient. However, the 642 assessments from 182 patients in a longitudinal study
may contain less or possibly even more information about a parameter than 642
assessments from 642 patients in a cross-sectional study. The longitudinal study
may contain less information because of the correlation between observations on
the same individual for whom assessments would not be independent.  On the other
hand, the longitudinal study monitoring the same individual over a range of ages
may be better able to detect the response in HRQoL to change in demographic (age)
and clinical variables at the individual level. The ratios given in Table 5 are a
measure of whether the longitudinal or cross-sectional study performs better for
each variable since these can be compared with the bench mark value of 3.5. A
higher ratio goes in favour of a longitudinal study and a lower ratio favours the
cross-sectional study. Looking at how the ratios change as the maximum score
reduces would indicate that a cross-sectional study may be suitable when the
maximum is high but a longitudinal study rapidly gains advantage for HRQoL
domains with small maxima. Also the large ratio required for age may explain why
the empirical longitudinal and cross-sectional studies gave such discrepant results
for age.
The sample sizes required to estimate parameter values to within a 30%
precision were surprising. A longitudinal sample size of 182 with, on average, 3.5
assessments per patient should be adequate to detect the significant effect of age,
B. cepacia complex and FEV1% predicted, if these were the only significant
variables, for domains with maxima in the range 15 to 50. However, the effect of
gender requires a considerably larger number of patients in a longitudinal study for
an effect to be detected. The effect of gender seems partially lost and this might be
due to the inclusion in the model of a random intercept for each patient. Intuitively
a random intercept should be included in the models and tests of whether the
intercept should be a random or fixed effect for the empirical data indicated that a
random intercept was required. These were tests for whether the intercept variance
and the covariance with other random effects were not significantly different to
zero. With a random intercept included, the failure to detect the effect of gender
ought not to bias judgements regarding the effect of the other variables.
Sample sizes to detect significant effects would clearly need to be larger if
more than four variables were included in the simulations and in the fitted models
because standard errors would be increased. If more variables were included in the
model simulations but were not included in the fitted model this would appear as
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extra binomial variation and it is not clear what influence this would have on ratios
and sample sizes. Most likely sample sizes would increase but the influence on the
ratios is not predictable. Also, the simulations of HRQoL contained two random
coefficients; the intercept and the gradient with FEV1% predicted. The two random
coefficients were generated uncorrelated in the simulations and the value, on which
FEV1% predicted was centred, was selected to reduce correlation in the parameter
estimates.  If some modest correlation was simulated then, again, the effect on ratios
and samples sizes would be difficult to predict.
The way in which the HRQoL was simulated may have impacted on the
sample sizes and ratios with which the two types of study have been compared. As
an alternative, the logit of the HRQoL binomial probability could have been
generated using the method described here but only for the first time point for each
patient. For later time points, the binomial probability value at the previously
recorded time point could have been adjusted by the change in demographic and
clinical variables since the earlier time point. This would have introduced additional
autocorrelation into the longitudinal data. The method used in the simulations
introduced autocorrelation in the HRQoL only through the autocorrelation in the
demographic and clinical variables. Again it is not possible to predict what
difference this would have made to the sample sizes and ratios. More work could
provide some answers.
All of the foregoing discussion has been concerned with statistical issues but
clearly the choice between a longitudinal study and a cross-sectional study is not
determined by statistics. There are many factors which influence the choice, not
least of which is the time scale under which funding is provided for research. Few
funders would fund a 12 year prospective study and the empirical study described
here was unfunded research. By necessity the study was single centred and had less
than 250 patients in total and was manageable within the staff time and resources
available. In contrast, the International Depression/anxiety Epidemiological Study
(TIDES) in the UK was a cross-sectional study which recruited about 45% of the
UK adult population in the CF Registry across 25 adult CF centres (Duff et al.,
2014). This large study recruited a total of 1780 adults and was a major undertaking
over a 30 month period. It would have been unlikely to have recruited more had it
continued beyond 30 months because in this type of study a saturation point can be
reached with a finite population of potential patients. A cross-sectional study,
therefore, of a particular patient group will be limited above by the population size
of the group and the willingness of the patients to participate in research. Statisticians
can simulate 10,000 patients but other researchers can only dream of obtaining such
sample sizes. The number of patients required for a cross-sectional study equivalent
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to a given longitudinal study might simply not be achievable. A longitudinal study
of a small number of patients will be bound to yield more information than a cross-
sectional study of an equally small number of patients. In this case, the researchers
should choose a longitudinal study and cultivate a lot of ‘patience’ rather than a lot
of ‘patients’.
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